Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

被引：0

作者：

DiNardo, C. ^{[1
]}

Stein, A. ^{[2
]}

Stein, E. ^{[3
]}

Fathi, A. ^{[4
]}

Frankfurt, O. ^{[5
]}

Schuh, A. ^{[6
]}

Doehner, H. ^{[7
]}

Martinelli, G. ^{[8
]}

Patel, P. ^{[9
]}

Raffoux, E. ^{[10
]}

Tan, P. ^{[11
]}

Zeidan, A. ^{[12
]}

de Botton, S. ^{[13
]}

Kantarjian, H. ^{[1
]}

Stone, R. ^{[14
]}

Lam, D. ^{[15
]}

Wang, X. ^{[15
]}

Gong, J. ^{[15
]}

Kapsalis, S. ^{[16
]}

Hickman, D. ^{[16
]}

Zhang, V. ^{[16
]}

Winkler, T. ^{[16
]}

Wu, B. ^{[16
]}

Vyas, P. ^{[17
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] City Hope Med Ctr, Duarte, CA USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[5] Northwestern Univ, Chicago, IL 60611 USA

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Ulm Univ Hosp, Ulm, Germany

[8] IRST, Meldola, Italy

[9] UT Southwestern Med Ctr, Dallas, TX USA

[10] Hop St Louis, Paris, France

[11] Royal Perth Hosp, Perth, WA, Australia

[12] Yale Canc Ctr, New Haven, CT USA

[13] Inst Gustave Roussy, Villejuif, France

[14] Dana Farber Canc Inst, Boston, MA 02115 USA

[15] Celgene, Summit, NJ USA

[16] Agios, Cambridge, MA USA

[17] Univ Oxford, Oxford, England

来源：

ANNALS OF HEMATOLOGY | 2019年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

40a

引用

页码：S40 / S41

页数：2

共 50 条

[41] AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Montesinos, Pau
Recher, Christian
Vives, Susana
Zarzycka, Ewa
Wang, Jianxiang
Bertani, Giambattista
Heuser, Michael
Calado, Rodrigo T.
Schuh, Andre C.
Yeh, Su-Peng
Daigle, Scott R.
Hui, Jianan
Zhang, Vickie
Pandya, Shuchi S.
Gianolio, Diego A.
de Botton, Stephane
Doehner, Hartmut
BLOOD, 2021, 138
[42] AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib plus Azacitidine Versus Placebo plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation
Dohner, Hartmut
Montesinos, Pau
Polo, Susana Vives
Zarzycka, Ewa
Wang, Jianxiang
Bertani, Giambattista
Heuser, Michael
Calado, Rodrigo T.
Schuh, Andre C.
Yeh, Su-Peng
de la Fuente, Adolfo
Cerchione, Claudio
Daigle, Scott R.
Hui, Jianan
Pandya, Shuchi S.
Gianolio, Diego A.
Recher, Christian
de Botton, Stephane
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S234 - S234
[43] Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
Dinardo, Courtney Denton
Schuh, Andre C.
Stein, Eytan M.
Montesinos, Pau
Wei, Andrew
De Botton, Stephane
Zeidan, Amer Methqal
Fathi, Amir Tahmasb
Quek, Lynn
Kantarjian, Hagop M.
Frattini, Mark G.
Lersch, Frederik
Gong, Jing
Franovic, Aleksandra
Vyas, Paresh
Dohner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[44] Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia
Fan, Bin
Chen, Yue
Yin, Feng
Hua, Lei
Almon, Caroline
Nabhan, Salah
Cooper, Michael
Yang, Hua
Hossain, Mohammad
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (04): : 429 - 441
[45] Investigations into rational combination approaches with ivosidenib in a mutant IDH1 acute myeloid leukemia patient-derived xenograft model.
Hudson, Christine
Narayanaswamy, Rohini
Ronseaux, Sebastien
Bowden, Chris
Nicolay, Brandon
CANCER RESEARCH, 2021, 81 (13)
[46] A Comparison of Acute Myeloid Leukemia (AML) Regimens: Hypomethylating Agents Combined with Ivosidenib or Venetoclax in Newly Diagnosed Patients with IDH1 Mutations: A Real-World Evidence Study
Smith, B. Douglas
Lachowiez, Curtis A.
Ambinder, Alexander Joseph
Binder, Gary
Angiolillo, Anne
Vestin, Assaf
Paglia, Robert
Potluri, Ravi
Papademetriou, Eros
LeBlanc, Thomas W.
BLOOD, 2023, 142
[47] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
Atluri, Himachandana
Maiti, Abhishek
Sasaki, Koji
Daver, Naval
Alvarado, Yesid
Hossain, Md Feroz
Wang, Xuemei
Pemmaraju, Naveen
Takahashi, Koichi
Borthakur, Gautam
Ferrajoli, Alessandra
Short, Nicholas
Abbas, Hussein A.
Ravandi, Farhad
Jabbour, Elias
Andreeff, Michael
Garcia-Manero, Guillermo
Kantarjian, Hagop
Konopleva, Marina
DiNardo, Courtney D.
BLOOD, 2022, 140 : 6170 - 6172
[48] Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
Wang, Lida
Song, Jiwu
Xiao, Xiangming
Li, Dianfang
Liu, Tianmeng
He, Xiaopo
JOURNAL OF CHEMOTHERAPY, 2024, 36 (03) : 202 - 207
[49] Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis
Wang, Lida
Song, Jiwu
Xiao, Xiangming
Li, Dianfang
Liu, Tianmeng
He, Xiaopo
JOURNAL OF CHEMOTHERAPY, 2023,
[50] Mutant Isocitrate Dehydrogenase Inhibitors, Enasidenib or Ivosidenib, in Combination With Azacitidine: Preliminary Results of a Phase 1b/2 Study in Patients With Newly Diagnosed Acute Myeloid Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 11

← 1 2 3 4 5 →